© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
June 10, 2022
Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.
September 30, 2021
In an interview with Targeted Oncology™, Phillip J. Koo, MD, discusses both the role of novel PSMA tracers in prostate cancer imaging and the promise that theranostics, including LuPSMA, hold for prostate cancer therapy.
September 27, 2021
In this second video of the series, Phillip J. Koo, MD, of the Banner MD Anderson Cancer Center explains the role of nuclear imaging (PET) and PSMA in the diagnosis and treatment of prostate cancer.